De-Risking Headline Risk: Merck Media Strategy Helps Company Ride Out ARBITER Data

A negative, head-to-head study questioning the role of Vytorin is presented at AHA: that sounds like a replay of the ENHANCE disaster. But here's the twist: Merck shares rallied after the data were released. What changed?